Universal Ibogaine Inc.
IBOGF
$0.018
$0.003221.62%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -40.11% | -33.96% | -2.88% | 25.08% | 1,326.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.11% | -33.96% | -2.88% | 25.08% | 1,326.80% |
| Cost of Revenue | -17.43% | -4.56% | 27.20% | 24.44% | 122.07% |
| Gross Profit | -93.75% | -107.66% | -52.13% | 28.23% | 220.65% |
| SG&A Expenses | -39.82% | -31.72% | -79.36% | 6.17% | -52.79% |
| Depreciation & Amortization | 3.47% | -4.54% | 7.89% | 11.05% | 17.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.30% | -9.70% | 11.49% | 14.34% | -8.57% |
| Operating Income | -29.83% | -86.43% | -276.32% | -3.39% | 76.91% |
| Income Before Tax | -30.13% | -65.84% | -175.00% | -76.87% | 72.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.13% | -65.84% | -175.00% | -76.87% | 72.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.13% | -65.84% | -175.00% | -76.87% | 72.02% |
| EBIT | -29.83% | -86.43% | -276.32% | -3.39% | 76.91% |
| EBITDA | -50.45% | -182.53% | -134.11% | -1.84% | 85.82% |
| EPS Basic | 22.22% | 0.00% | -90.91% | -15.79% | 70.97% |
| Normalized Basic EPS | 20.00% | 0.00% | -100.00% | 33.33% | 75.00% |
| EPS Diluted | 22.22% | 0.00% | -163.64% | -15.79% | 70.97% |
| Normalized Diluted EPS | 20.00% | 0.00% | -100.00% | 33.33% | 75.00% |
| Average Basic Shares Outstanding | 60.91% | 60.93% | 37.25% | 48.54% | 0.16% |
| Average Diluted Shares Outstanding | 60.91% | 60.93% | 37.25% | 48.54% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |